Lilly Endowment 13F Portfolio

The “biggest buys” widget is empty because there were none — when your entire book is Eli Lilly, conviction is measured in what you don’t do. The endowment chose not to diversify, not to reallocate to other sectors, and not to layer in any hedges via other healthcare names.

That inaction is itself a statement: management believes Eli Lilly’s pipeline, obesity and metabolic franchises, and broader innovation engine still justify having the endowment’s investable public equity capital effectively stapled to one ticker. The 3‑year annualized return of 36.8% is being allowed to compound unfettered, with no attempt this quarter to smooth the ride via new positions.

In practical terms, rising conviction shows up as persistence rather than purchases: six consecutive quarters holding Lilly, no new names, and no apparent effort to preemptively diversify ahead of potential drawdowns. The portfolio is a pure bet that Eli Lilly’s current era is not a top but a midpoint.

The one visible action this quarter is a -1.7% reduction in Eli Lilly shares, cutting the stake by about $1.82B on an estimated basis. Against a $108.4B position with decades of embedded gains, that’s more of a pressure release valve than an exit path.

There are three likely motivations for a move this small. First, classic endowment discipline: harvest a fraction of a parabolic move, especially after a 30.41% quarter, while keeping the strategic exposure intact. Second, liquidity and grant‑making needs — tapping a slice of an overgrown asset base to fund the philanthropic mission. Third, risk optics: it signals to boards and stakeholders that portfolio risk is being monitored, even if not fundamentally reduced.

What it is not is a repudiation of Eli Lilly. A genuine conviction break would show up as a double‑digit percentage cut in shares or the introduction of alternative growth engines; neither is present here. The endowment is clearly funding current needs with gains while letting the core bet ride.

On paper, sector allocation is boring: 100.0% Health Care last quarter, 100.0% Health Care this quarter, all through Eli Lilly. Beneath that still surface is the more interesting reality that the endowment is comfortable tying its public‑equity risk to one therapeutic and regulatory complex.

No new sectors, no technology or industrial ballast, no defensive consumer names entered the book. The endowment is leaving its fate tethered to drug pricing policy, obesity‑drug uptake, and the durability of Eli Lilly’s innovation edge, rather than diluting that exposure with other healthcare subsectors or non‑correlated assets.

The small trim does nothing to alter that profile. Sector risk remains highly concentrated, and the managers appear to view diversification as something handled outside the 13F equity sleeve — through private assets, fixed income, or other vehicles — rather than within this public‑equity reporting universe.

Put together, 2026‑Q2 says Lilly Endowment is still betting that Eli Lilly has a long runway of value creation ahead, and that the volatility and idiosyncratic risk are acceptable given the upside. The modest share reduction is about calibrating exposure, not abandoning the franchise.

Investors watching this endowment should interpret the quarter as a high‑conviction hold with incremental de‑risking. The core bet — that Eli Lilly’s current drug portfolio and pipeline can keep compounding capital at unusually high rates — remains unchallenged.

Going forward, the real inflection point to watch is not more small trims, but whether new names finally appear. As long as the 13F shows Eli Lilly at 100.0% with only token reductions, the message is unchanged: this is a deliberate, mission‑tied embrace of concentration, with risk management handled at the margins rather than through diversification.